These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29244145)

  • 1. Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma.
    Mahlokozera T; Vellimana AK; Li T; Mao DD; Zohny ZS; Kim DH; Tran DD; Marcus DS; Fouke SJ; Campian JL; Dunn GP; Miller CA; Kim AH
    Neuro Oncol; 2018 Mar; 20(4):472-483. PubMed ID: 29244145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.
    Kim H; Zheng S; Amini SS; Virk SM; Mikkelsen T; Brat DJ; Grimsby J; Sougnez C; Muller F; Hu J; Sloan AE; Cohen ML; Van Meir EG; Scarpace L; Laird PW; Weinstein JN; Lander ES; Gabriel S; Getz G; Meyerson M; Chin L; Barnholtz-Sloan JS; Verhaak RG
    Genome Res; 2015 Mar; 25(3):316-27. PubMed ID: 25650244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.
    Rosenberg S; Verreault M; Schmitt C; Guegan J; Guehennec J; Levasseur C; Marie Y; Bielle F; Mokhtari K; Hoang-Xuan K; Ligon K; Sanson M; Delattre JY; Idbaih A
    Neuro Oncol; 2017 Feb; 19(2):219-228. PubMed ID: 27571888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolutionary Trajectories of IDH
    Körber V; Yang J; Barah P; Wu Y; Stichel D; Gu Z; Fletcher MNC; Jones D; Hentschel B; Lamszus K; Tonn JC; Schackert G; Sabel M; Felsberg J; Zacher A; Kaulich K; Hübschmann D; Herold-Mende C; von Deimling A; Weller M; Radlwimmer B; Schlesner M; Reifenberger G; Höfer T; Lichter P
    Cancer Cell; 2019 Apr; 35(4):692-704.e12. PubMed ID: 30905762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study.
    Tabone T; Abuhusain HJ; Nowak AK; ; Erber WN; McDonald KL
    J Clin Pathol; 2014 Jul; 67(7):550-5. PubMed ID: 24695838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
    Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
    Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma.
    Diamandis P; Ferrer-Luna R; Huang RY; Folkerth RD; Ligon AH; Wen PY; Beroukhim R; Ligon KL; Ramkissoon SH
    Diagn Pathol; 2016 Jan; 11():13. PubMed ID: 26817999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
    Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Yamaguchi S; Tanino M; Murata J; Houkin K
    Brain Tumor Pathol; 2013 Apr; 30(2):67-72. PubMed ID: 22752663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing.
    Francis JM; Zhang CZ; Maire CL; Jung J; Manzo VE; Adalsteinsson VA; Homer H; Haidar S; Blumenstiel B; Pedamallu CS; Ligon AH; Love JC; Meyerson M; Ligon KL
    Cancer Discov; 2014 Aug; 4(8):956-71. PubMed ID: 24893890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes.
    Kumar A; Boyle EA; Tokita M; Mikheev AM; Sanger MC; Girard E; Silber JR; Gonzalez-Cuyar LF; Hiatt JB; Adey A; Lee C; Kitzman JO; Born DE; Silbergeld DL; Olson JM; Rostomily RC; Shendure J
    Genome Biol; 2014 Dec; 15(12):530. PubMed ID: 25608559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by 1H-magnetic resonance spectroscopy.
    Tang C; Guo J; Chen H; Yao CJ; Zhuang DX; Wang Y; Tang WJ; Ren G; Yao Y; Wu JS; Mao Y; Zhou LF
    Int J Clin Exp Pathol; 2015; 8(5):5327-35. PubMed ID: 26191234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Microenvironment Characterization in Glioblastoma Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures.
    Zhang J; Xiao X; Zhang X; Hua W
    J Mol Neurosci; 2020 May; 70(5):738-750. PubMed ID: 32006162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Genomic Sequencing Reveals Different Evolutionary Patterns Between Locally and Distally Recurrent Glioblastomas.
    Yoon N; Kim HS; Lee JW; Lee EJ; Maeng LS; Yoon WS
    Cancer Genomics Proteomics; 2020; 17(6):803-812. PubMed ID: 33099481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of TERT Promoter Mutations Using Targeted Next-Generation Sequencing: Overcoming GC Bias through Trial and Error.
    Lee H; Lee B; Kim DG; Cho YA; Kim JS; Suh YL
    Cancer Res Treat; 2022 Jan; 54(1):75-83. PubMed ID: 33940787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas.
    Abou-El-Ardat K; Seifert M; Becker K; Eisenreich S; Lehmann M; Hackmann K; Rump A; Meijer G; Carvalho B; Temme A; Schackert G; Schröck E; Krex D; Klink B
    Neuro Oncol; 2017 Apr; 19(4):546-557. PubMed ID: 28201779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
    Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
    Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutations in primary and secondary glioblastomas.
    Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
    Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.